

To whom it may concern

DNV MEDCERT GmbH Pilatuspool 2 20355 Hamburg Germany

Tel: +49 40 2263325-0 E-mail: Medcert-Info@dnv.com

 Date:
 Our reference:

 2023-06-28
 QS-2708

Notified Body Confirmation Letter Certification No:N/A

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices

To whom it may concern,

This letter confirms that DNV Medcert GmbH, a Notified Body (NB), designated against Regulation (EU) 2017/745 (MDR) and identified by the number 0482 on Nando¹, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer.

Amsino Healthcare (USA), Inc. 330 Corporate Woods Parkway IL 60061-3107 Vernon Hills United States of America SRN²: US-MF-000007234

The devices covered by the formal application and the written agreement mentioned above are identified in the tables (in the appendix of this letter). Table 1 identifies the devices for which an MDR application has been received, a written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by 20 March 2023 for the relevant devices.

DNV MEDCERT GmbH, Hamburg, HRB 55912, Tax ID: 48/715/05387, VAT ID: DE164312394 Managing Director: Klaus-Dieter Ziel. The place of jurisdicton and fulfilment is Hamburg. The terms and conditions of DNV MEDCERT GmbH apply in their latest up to date version. The German law applies. Bank accounts: IBAN: DE58 2007 0000 0277 8090 00, BIC: DEUTDEHHXXX (Deutsche Bank), or IBAN: DE13 2005 0550 1382 1207 88, BIC: HASPDEHHXXX (Hamburger Sparkasse). 520109 EN Rev 2 2022:11.30

¹ Nando (New Approach Notified and Designated Organisations) Information System, <u>https://ec.europa.eu/growth/tools-databases/nando/</u>

² Single registration number (SRN) according to Article 31 (2) of MDR.



Page 2 of 3

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by EU 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding well established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips, and connectors)
- 31 December 2028 for other Class IIb devices, Class IIa devices, Class I devices placed on the market in sterile condition or have a measuring function
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

For DNV MEDCERT Growth
Lorenz Runge Chief Certification
Appendix (see following pages): • Table 1 and Table 2 • Revision history



Page 3 of 3 Appendix

 Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
Humidification Systems	Class IIa	N/A	Certificate 2708GB414190221; NB 0482
Inhalation therapy humidification liquids	Class IIb excluding Class IIb implantable non-WET	N/A	Certificate 2708GB414190221; NB 0482

 Table 2: Devices covered by this letter and for which the NB is <u>NOT</u> responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
None	None	None	None

Confirmation Letter Revision History:

Date	NB internal reference traceable to each version of the letter	Action	181
2023-06-29	N/A	Initial issue	

100